Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group

Basit Öğe Kaydı
dc.authoridSahin, Bahadir/0000-0002-4874-4178
dc.authoridcinar, onder/0000-0002-0107-5843
dc.authoridCihan, Ahmet/0000-0001-5586-8673
dc.authoridKAZAZ, ILKE ONUR/0000-0002-2106-0016
dc.authoridure, iyimser/0000-0002-4653-576X
dc.authoridTurunc, Tahsin/0000-0002-7936-2172
dc.authoridYildirim, Omer/0000-0001-7620-995X
dc.contributor.authorCinar, Onder
dc.contributor.authorTurunc, Tahsin
dc.contributor.authorKazaz, Ilke Onur
dc.contributor.authorYildirim, Omer
dc.contributor.authorDeliktas, Hasan
dc.contributor.authorCihan, Ahmet
dc.contributor.authorGudeloglu, Ahmet
dc.date.accessioned2024-11-07T13:35:26Z
dc.date.available2024-11-07T13:35:26Z
dc.date.issued2021
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractAims of the study The aim of this study was to investigate the impact of testosterone deficiency on cognitive functions in metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). Methods In this multicentric prospective study, 65 metastatic prostate cancer patients were evaluated. Demographic and clinical data were recorded. Cognitive functions were assessed using the Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test-Revised, and the Trail Making Test. Depressive symptoms were assessed using the Beck Depression Inventory. Cognitive functions and depressive symptoms were recorded before the androgen deprivation therapy and at the 3- and 6-month follow-ups. Results At the basal cognitive assessment, the mean Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test-Revised scores were 25.84 +/- 17.54, 32.68 +/- 10.60, and 17.63 +/- 11.23, respectively, and the mean time for the Trail Making Test was 221.56 +/- 92.44 seconds, and were similar at the 3-month, and 6-month controls (P > .05). The mean pretreatment, third and sixth month testosterone levels were 381.40 +/- 157.53 ng/dL, 21.61 +/- 9.09 ng/dL and 12.25 +/- 6.45 ng/dL (P < .05), and the total PSA levels were 46.46 +/- 37.83 ng/mL, 1.41 +/- 3.31 ng/mL and 0.08 +/- 0.14 ng/mL (P < .05), respectively. Conclusion The ADT in patients with metastatic prostate cancer does not affect patients' cognitive functions and depressive symptoms. However, further prospective randomised studies with higher cohorts and longer follow-up periods are needed.
dc.identifier.doi10.1111/ijcp.14095
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue6
dc.identifier.pmid33619782
dc.identifier.scopus2-s2.0-85101838722
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1111/ijcp.14095
dc.identifier.urihttps://hdl.handle.net/11480/16506
dc.identifier.volume75
dc.identifier.wosWOS:000622758100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-Hindawi
dc.relation.ispartofInternational Journal of Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectMen
dc.subjectImpairment
dc.subjectTestosterone
dc.titleEffects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu